How Novo Revitalized Its Rare Disease Operations
There is more to the Danish major than diabetes and Ludovic Helfgott gave In Vivo an insight to the firm’s ambitious plans for its renamed rare diseases division.
You may also be interested in...
Novo's head of rare disease Ludovic Helfgott talked to Scrip about the $1.1bn acquisition and expansion into sickle cell disease.
The Danish firm’s injectable growth hormone analogue has succeeded in a late-stage study of children with a growth disorder and offers more convenient dosing that could improve adherence.
The Denmark-headquartered major is impressed with what it has seen in Dicerna in the two years since the companies teamed up and is paying an 80% premium to get hold of the US firm's RNAi technology platforms.